NATCO Pharma Asia, a wholly-owned subsidiary (WOS) of Natco Pharma (NATCO) incorporated in Singapore, has acquired 49% of shareholding in PT NATCO Lotus Farma from PT Lotus Farma Indonesia. NATCO already owns 51% of PT NATCO Lotus Farma. Post this acquisition, NATCO along with its WOS wholly-owns 100% of PT NATCO Lotus Farma.Powered by Capital Market - Live News

Natco Pharma will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live News

Natco Pharma has appointed Amit Parekh as Executive Vice President - Finance and Accounts of the Company with effect from 2nd December 2025 and as part of the Company`s structured succession planning; subject to necessary approvals; Amit Parekh will succeed S.V.V.N. Appa Rao, Chief Financial Officer of the Company at the Board meeting to be held in the month of February 2026. Powered by Capital Market - Live News

Natco Pharma announced that ICRA has reaffirmed/ assigned the rating ICRA AA; Stable/ ICRA A1+ for various debt facilities of the company. Powered by Capital Market - Live News

Natco Pharma today announced conclusion of US FDA Inspection at its Manali, Chennai, Active Pharmaceutical Ingredients (API) Unit. The inspection was conducted from 17 - 21 November 2025. On conclusion of the inspection, the Company received seven observations in the Form-483. The Company believes that the observations are procedural in nature. The Company is confident to address these observations comprehensively. Powered by Capital Market - Live News